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ABSTRACT 41 
The Achilles tendon (AT) has the capacity to store and release elastic energy during 42 
walking, contributing to metabolic energy savings. In diabetes patients, it is 43 
hypothesised that a stiffer Achilles tendon may reduce the capacity for energy saving 44 
through this mechanism, thereby contributing to an increased metabolic cost of walking 45 
(CoW). The aim of this study was to investigate the effects of diabetes and diabetic 46 
peripheral neuropathy (DPN) on the Achilles tendon and plantarflexor muscle-tendon 47 
unit behaviour during walking. Twenty three non-diabetic controls (Ctrl); 20 diabetic 48 
patients without peripheral neuropathy (DM) and 13 patients with moderate/severe 49 
DPN, underwent gait analysis using a motion analysis system, force plates and 50 
ultrasound measurements of the gastrocnemius muscle, using a muscle model to 51 
determine Achilles tendon and muscle-tendon length changes. During walking, the DM 52 
and particularly the DPN group displayed significantly less Achilles tendon elongation 53 
(Ctrl: 1.81; DM 1.66; DPN: 1.54 cm), higher tendon stiffness (Ctrl: 210; DM: 231; DPN: 54 
240 N/mm) and higher tendon hysteresis (Ctrl: 18; DM: 21; DPN: 24 %) compared to 55 
controls. The muscle fascicles of the gastrocnemius underwent very small length 56 
changes in all groups during walking (~0.43cm), with the smallest length changes in the 57 
DPN group. Achilles tendon forces were significantly lower in the diabetes groups 58 
compared to controls (Ctrl: 2666; DM: 2609; DPN: 2150 N). The results strongly point 59 
towards the reduced energy saving capacity of the Achilles tendon during walking in 60 
diabetes patients as an important factor contributing to the increased metabolic CoW in 61 
these patients. 62 
Keywords: elastic energy storage, tendon stiffness, lower limb, biomechanics, diabetes. 63 
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 64 
New & Noteworthy 65 
From measurements taken during walking we observed that the Achilles tendon in 66 
people with diabetes and particularly people with diabetic peripheral neuropathy was 67 
stiffer, elongated less and was subject to lower forces compared to controls without 68 
diabetes. These altered properties of the Achilles tendon in people with diabetes reduce 69 
the tendon’s energy saving capacity and contribute towards the higher metabolic energy 70 
cost of walking in these patients.   71 
 72 
INTRODUCTION 73 
Diabetes mellitus (DM) is a very prevalent global chronic disease in older adults and is 74 
associated with a number of complications including cardiovascular disease, peripheral 75 
arterial disease, retinopathy and poor wound healing (16, 14). One of the most common 76 
complications of diabetes is diabetic peripheral neuropathy (DPN), with the incidence 77 
reported to range between 13 and 68% (44, 6). Diabetes and DPN impact negatively on 78 
gait and mobility with implications for quality of life. Diabetes and DPN cause muscle 79 
weakness and affect sensory perception altering walking strategy and causing 80 
impairments to balance control (13, 30, 20, 5). 81 
The muscle-tendon complex is central to all movement tasks, with skeletal muscle 82 
generating force, which is transmitted to the skeleton via viscoelastic tendons. In 83 
addition to their force transmitting role, tendons also play an important role in energy 84 
saving during walking by storing (during stretching) and returning (upon recoil) elastic 85 
energy (37, 38, 39, 2). In particular, the Achilles tendon is a long tendon that is 86 
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important for storing and releasing elastic energy during walking and as such, plays an 87 
important role in metabolic energy saving, as it actually ‘spares’ the muscle from 88 
performing a large part of the work (3).  89 
Both muscles and tendons are highly malleable tissues, which can modify their 90 
properties in response to the habitual level of physiological loading and also the 91 
metabolic environment (36, 1, 17). Animal studies show that diabetes causes non-92 
enzymatic glycation of soft tissues, including tendons (34). This non-enzymatic glycation 93 
causes increased cross-linking, increasing the stiffness and modulus of the tendon (35, 94 
33). Stiffening of the tendon reduces the degree to which it can be stretched, affecting 95 
its potential for storing (and subsequently releasing) elastic strain energy during walking 96 
and also limiting the ankle joint range of motion (11, 19, 29). In humans, calcification 97 
and fascicle disruption have been observed in the diabetic human Achilles tendon (4). 98 
Tendons exhibit relatively low mechanical hysteresis, which is defined as the energy 99 
lost upon recoil of the tendon (27). In addition to tendon stiffness, the hysteresis of the 100 
tendon could also be affected by diabetes. Hysteresis has been shown to increase in 101 
humans with ageing (37). An increase in hysteresis would also reduce metabolic energy 102 
saving by the Achilles tendon during walking.  103 
In dynamometry tests, Couppé et al. (10) found Achilles tendon stiffness and skin 104 
connective tissue cross-linking were greater in diabetes patients compared with 105 
controls. Cronin et al. (11) found that Achilles tendon length changes during walking at 106 
self-selected speed were attenuated in diabetes patients and that this was inversely 107 
correlated with diabetes duration.  108 
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The impact of changes in Achilles tendon and plantarflexor muscle function induced by 109 
diabetes and diabetic neuropathy remain unknown during walking. The aim of this study 110 
was to investigate the effects of diabetes and diabetic peripheral neuropathy on plantar 111 
flexor muscle-tendon behaviour during walking at self-selected and controlled speeds. 112 
We hypothesized that the Achilles tendon would function in a manner that reduced its 113 
energy contribution during walking in diabetes patients and particularly in those with 114 
diabetic neuropathy compared to controls. As a result, a greater contribution would be 115 
required from the plantarflexor muscles for walking, requiring more energy and 116 
contributing to the higher cost of walking (CoW) that we have recently reported in 117 
people with diabetes (32). 118 
 119 
MATERIALS AND METHODS 120 
Participants 121 
Fifty-six participants were involved in this study. Participants were allocated into one of 122 
three groups based upon defined criteria: patients with diabetes and moderate-severe 123 
peripheral neuropathy (DPN, n=13), patients with diabetes but no neuropathy (DM, 124 
n=20) and healthy controls without diabetes or peripheral neuropathy (Ctrl, n=23). Major 125 
exclusion criteria included: disorders of the vestibular system, severe vascular disease, 126 
neurological, rheumatic disease, cerebral injury, unstable ischemic heart, 127 
musculoskeletal injury, foot or lower limb amputation (amputation of the hallux; 128 
amputation of more than two lesser toes on one foot; amputation of part of/whole foot) 129 
and open foot ulcer and recent surgery affecting gait. Participant characteristics are 130 
displayed in Table 1. 131 
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Diagnosis of Diabetic Peripheral Neuropathy  132 
The presence and severity of peripheral neuropathy was assessed by using the 133 
modified Neuropathy Disability Score (mNDS) and the vibration perception threshold 134 
(VPT). The mNDS is a composite score taken from tests measuring the participant’s 135 
ability to discriminate temperature, detect pain, vibration and the Achilles tendon reflex 136 
(6). The VPT is an assessment performed using the probe of a neurothesiometer on the 137 
apex of the hallux and increasing the level of vibration until detected by the participant. 138 
A random blood glucose test was performed in the Ctrl group to confirm the absence of 139 
diabetes (<7 mmol/l) and the above neuropathy tests were conducted to confirm the 140 
absence of neuropathy in the Ctrl group resulting from any aetiology. 141 
 142 
Gait analysis 143 
Gait analysis was performed for the purpose of assessing the contribution of the 144 
plantarflexor muscle-tendon complex and the capacity for elastic energy storage and 145 
release via the Achilles tendon. To investigate whether the changes are dependent on 146 
the walking speed we asked participants to walk along a 10-metre walkway in the gait 147 
laboratory at their self-selected speed, as well as at a standardized speed of 1.0 m/s. 148 
Walking at the standardized speed was controlled by measuring the velocity of a marker 149 
attached to the sacrum after each trial from the motion analysis data and providing 150 
immediate feedback for participants as to whether they needed to walk more quickly or 151 
more slowly on the next trial to achieve the required speed (1.0 m/s). Kinematic data 152 
were collected at 100 Hz using a 10-camera Vicon motion capture system (Vicon, 153 
Oxford, UK) and a full-body modified Plug-In-Gait marker set consisting of 54 markers. 154 
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Where possible motion analysis markers were placed directly onto the skin; to minimise 155 
movement artefacts resulting from loose clothing, all participants wore tight-fitting shorts 156 
and t-shirts. Ground reaction forces were measured at 1000 Hz from three force 157 
platforms (Kistler, Zurich, Switzerland) embedded into the walkway and synchronised 158 
with the kinematic data. We have used standard procedures and systems for the 159 
calculation of joint moments that are used routinely and have been widely accepted by 160 
the biomechanics community (43, 9). Walking trials were repeated until three ‘clean’ foot 161 
contacts with the force platforms were made with right limb, for both speed conditions. 162 
During walking, an ultrasonographic imaging device (Aloka SSD-5000, Tokyo, Japan) 163 
operating at 25 Hz was used to measure gastrocnemius medialis (MG) muscle fascicle 164 
length changes in vivo. For these measurements, a linear 7.5 MHz probe with 60 mm 165 
field of view was secured around the right lower leg in the mid-sagittal plane of the MG 166 
muscle with a custom-built fixation device (Fig. 1). The ultrasound scanning was 167 
synchronized with recordings of the kinematic and kinetic data. We have previously 168 
shown a high reliability for this technique in measuring fascicle lengths, with an intra-169 
class correlation coefficient of 0.8 (42). All participants wore specialist diabetic shoes 170 
(MedSurg, Darco, Raisting, Germany) with a neutral foot-bed, ensuring the diabetic 171 
patients walked with safe, appropriate footwear whilst controlling for the effects of 172 
footwear on the measured variables by standardising across all groups (Fig. 1). 173 
 174 
Dynamometry measurements: Measurement of Maximal Plantarflexion Strength 175 
Isometric plantarflexor maximal voluntary contraction (MVC) joint moment (maximum 176 
strength) was recorded with participants laying prone with the knee in full extension. 177 
8 
 
The axis of rotation of the ankle, defined as the line connecting the two malleoli, was 178 
carefully aligned with the axis of rotation of the dynamometer and the right foot secured 179 
to the foot adapter of an isokinetic dynamometer (Cybex NORM, Cybex International, 180 
New York, NY, USA). Straps were used around the ankle and also the hips to prevent 181 
extraneous movements during maximal plantarflexions. Prior to testing subjects became 182 
familiarised with the procedures involved. Participants were instructed to perform 183 
maximal isometric plantarflexion contractions at joint angles of 0, 5 and 10 degrees of 184 
dorsiflexion, where zero degrees was neutral ankle position: the footplate of the 185 
dynamometer perpendicular to the longitudinal axis of the tibia. The subjects were 186 
verbally encouraged to produce their maximum effort. Contractions were performed in a 187 
randomized order. Two contractions were performed at each ankle angle by allowing a 188 
1-min rest interval between bouts and the highest value was considered as the MVC at 189 
each ankle angle. Results were subsequently normalised to body mass. 190 
 191 
Data processing 192 
The purpose of the data analysis was to quantify the Achilles tendon and plantarflexor 193 
muscle-tendon complex characteristics during walking. The MG muscle was assessed 194 
as representative of the plantarflexor muscle group (41, 44) and measured from every 195 
frame of the ultrasound recordings throughout the entire stance phase. On each 196 
ultrasound frame, three lines were defined automatically using a custom-script written in 197 
MATLAB software (12): one line tracked the superficial aponeurosis, a second line was 198 
matched with the deep aponeurosis, and a third line defined the fascicular path of the 199 
fascicle movement. From these three lines, fascicle length and pennation angle were 200 
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calculated on each frame of ultrasound data. Muscle fascicle length was defined as the 201 
distance between the superficial and deep aponeurosis parallel to the lines of 202 
collagenous tissue. Pennation angle (α) was defined as the angle between the 203 
collagenous tissue and the deep aponeurosis, since this deep pennation angle is the 204 
one through which force is transmitted along the tendon. The equations by Menegaldo 205 
et al. Grieve et al. (10) were used to calculate the MG muscle-tendon complex (MTC) 206 
length change (muscle plus free tendon and aponeurosis in both distal and proximal 207 
ends) using the fascicle length changes and the ankle and knee joint displacements 208 
measured during walking over the stance phase. The length of the tendon (including 209 
both the free tendon and aponeurosis) was found by subtracting muscle fascicle length 210 
projected in the direction of the line of force application from the muscle–tendon 211 
complex (MTC) length for each time instant. Thus: 212 
l 
t 
= l 
MTC – l m cos α 213 
 214 
where l 
t
 is the length of the tendon, l 
MTC 
is the length of the MTC, l 
m
 is the 215 
ultrasound-measured muscle fascicle length, and α is the ultrasound-measured 216 
pennation angle.  217 
Real-time ultrasound scanning was used to determine MG muscle fascicle length 218 
changes, while musculotendon complex (MTC) length changes were estimated from 219 
ankle and knee joint kinematics. Muscle fascicle and tendon properties were assumed 220 
to be consistent along the length of the MTC. The muscle fascicles were also assumed 221 
to be parallel to one another. The validity and reliability of the ultrasound measurements 222 
in vivo during walking have been critically assessed in other studies on the same and 223 
similar populations, reporting ICC values between 0.78 and 0.94 (21, 28, 31, 41). 224 
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Achilles tendon force calculation and magnetic resonance imaging scanning  225 
Achilles tendon forces were calculated during walking throughout the stance phase by 226 
dividing the net plantarflexion joint moments (Nm) by the Achilles tendon internal 227 
moment arm length measured using a 0.25T magnetic resonance imaging (MRI) 228 
scanner (E-Scan, Esaote Biomedica, Genoa, Italy). The MRI scanning was performed 229 
with the participant in the upright standing position (i.e., full weight-bearing MRI) to 230 
mimic as closely as possible the conditions experienced on the ankle joint and Achilles 231 
tendon during walking. To calculate the Achilles tendon moment arm we used the 232 
Reauleaux method for identification of the ankle joint centre of a rotation, with the 233 
principle of a segment (the talus) rotating about a stationary (tibia) segment (40, 26). 234 
The centre of rotation was first defined using MRI images taken at 10 degrees of 235 
plantarflexion and 10 degrees of dorsiflexion, after which the distance between the 236 
Achilles tendon action line and the centre of rotation was measured on an MRI scan 237 
performed at the neutral ankle position.  238 
The plantarflexion joint moments were derived from the kinematic and kinetic data using 239 
Visual 3D software (C-motion Inc., MD, USA). Elongation of the Achilles tendon was 240 
calculated as described in the above section. The Achilles tendon force and elongation 241 
were normalised to 100 points to represent the entire stance phase. Therefore, the 242 
Achilles tendon force-elongation curve was derived, as shown in Fig. 5, where the 243 
loading phase (arrow pointing up) represents 10-70% of the stance phase and the 244 
unloading phase (arrow pointing down) the final 30%, as described in Table 2.  245 
 246 
Stiffness and hysteresis during walking 247 
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The Achilles tendon stiffness was calculated from the measurements taken during 248 
walking as the slope of the loading force-elongation curve by dividing the estimated 249 
tendon force (N) by the tendon’s elongation (mm) over a force region between 500 and 250 
1,500 N. This force region (500-1,500 N) was selected because it allowed comparison 251 
between groups over a common force region and enabled the use of measured data 252 
points on the force-elongation curve without the need to extrapolate. Mechanical 253 
hysteresis is a measure of the energy dissipated upon tendon recoil and converted to 254 
heat, an important feature of the mechanical properties of tendon. Mechanical 255 
hysteresis was defined as the area between the loading (L) and unloading (UnL) curves 256 
and expressed as a percentage: 257 
Mechanical hysteresis = (L - UnL) / L∙100 258 
 259 
Statistics 260 
A one-way analysis of variance (ANOVA) was performed for all variables to assess 261 
between group differences (Ctrl; DM; DPN). If the ANOVA was significant, a Fisher’s 262 
least significant difference (LSD) post-hoc test was used to test for differences between 263 
the diabetes groups (DM and DPN) and the control group. All values presented are 264 
means and standard deviation. Significance was accepted at p<0.05. 265 
 266 
RESULTS 267 
 268 
Participant characteristics  269 
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Participant characteristics are shown in Table 1. There were no significant differences 270 
between the groups in age and BMI (Table 1). 271 
 272 
Peripheral neuropathy assessments  273 
As expected, the DPN group displayed significantly higher values for the VPT and the 274 
mNDS compared to the Ctrl group (Table 1). The VPT and mNDS for the DM group 275 
were not significantly different from the Ctrl, underlining that this diabetes patient group 276 
had no neuropathy (Table 1). 277 
 278 
Lower limb kinetics and kinematics during walking 279 
Peak ankle plantarflexion joint moments were significantly lower (P<0.01) in the DPN 280 
and the DM compared to the Ctrl group for both self-selected and 1.0 m/s walking 281 
speeds (Table 2). A significantly (P<0.01) lower ankle and knee joint range of motion 282 
(RoM) was observed in the DPN and the DM groups compared to the Ctrl group for self-283 
selected and 1.0 m/s walking speeds (Table 2). 284 
 285 
Plantarflexor muscle-tendon unit behaviour during walking  286 
There were significant differences in the tendon length change between the groups at 287 
self-selected walking speed (Ctrl: 1.81 cm; DM 1.66 cm; DPN: 1.54 cm; P<0.01) as well 288 
as 1.0 m/s (Ctrl: 1.67 cm; DM 1.51 cm; DPN: 1.47 cm; P<0.01), where the DPN group 289 
expressed smaller tendon length changes. During walking, the DM and particularly the 290 
DPN groups displayed significantly higher tendon stiffness (Ctrl: 210; DM: 231; DPN: 291 
240 N/mm: P<0.01) and higher tendon hysteresis (Ctrl: 18; DM: 21; DPN: 24%: P<0.01) 292 
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compared to controls. There were no differences in the fascicle lengths during standing 293 
between the groups (P>0.05). Average fascicle length change data during the stance 294 
phase show that the DPN group was significantly lower (P<0.01) than the Ctrl group for 295 
both self-selected speed and 1.0 m/s during two different phases, 10-70% and 70-100% 296 
of the stance (Table 2), while the DM group was different from the Ctrl group only at 1.0 297 
m/s (Table 2). Significant differences in the MTC length change were found between the 298 
DPN and the Ctrl as well as the DM and the Ctrl groups for both walking speeds (Table 299 
2). Significant differences in the pennation angle changes were found between DPN 300 
and the Ctrl as well as the DM and the Ctrl groups for both speeds during loading and 301 
unloading phases (Table 2).  302 
  303 
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DISCUSSION 304 
This study has shown for the first time that there is reduced Achilles tendon elongation 305 
during the loading phase of walking (10-70% stance) and reduced tendon recoil during 306 
the subsequent propulsive phase (70-100% stance) in people with diabetes and to the 307 
greatest extent in those with DPN compared to controls (Table 2; Fig. 3). Further 308 
novelty is in uncovering the mechanism of this during walking, by showing that people 309 
with diabetes and particularly those with DPN demonstrated a higher stiffness and 310 
hysteresis of the Achilles tendon compared to the Ctrl group (Fig. 4; Table 5). Taken 311 
together the present findings strongly indicate a reduced elastic energy contribution 312 
from the Achilles tendon during walking in people with diabetes and to a greater extent 313 
in those with DPN, with implications for increasing the metabolic CoW in patients with 314 
diabetes and DPN as we have recently shown (32).  315 
The increased tendon stiffness observed in the diabetes groups shows that for the 316 
same application of force, the Achilles tendon is less extensible during walking, which 317 
means that less energy can be stored. The increased stiffness is further compounded 318 
by the fact that less force is applied on the Achilles tendon in the DM and particularly 319 
the DPN groups (Fig 5; Table 2). The lower tendon forces applied during walking in 320 
diabetic patients is the result of lower joint moments being developed, which reflect a 321 
natural strategy to lower the demands of walking (7, 8, 22). This requirement to lower 322 
the demands of walking stems from the lower muscular capabilities of diabetes patients, 323 
exemplified by the lower maximum plantarflexor strength observed in both diabetes 324 
groups of the present study (Fig. 6). The maximum plantarflexor strength deficits were 325 
most marked as the ankle moved further into dorsiflexion (Fig. 6), which is closely 326 
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aligned with the position of the ankle during walking when the Achilles tendon is 327 
undergoing elongation (Fig. 3 & 4). Hence, lower moments developed while the ankle is 328 
in dorsiflexion during walking means lower forces applied to elongate and store energy 329 
within the Achilles tendon.  330 
Once energy is stored in the Achilles tendon, the majority is returned upon tendon 331 
recoil, but some is lost due to internal damping, known as hysteresis. It was found that 332 
Achilles tendon hysteresis was significantly higher in people with diabetes, and to the 333 
greatest extent in those with DPN compared to controls. This further compounds the 334 
effect of reduced energy stored in the tendon upon loading resulting from increased 335 
tendon stiffness, since a lower proportion of the energy stored will be returned upon 336 
recoil.     337 
The results indicate that the MTC length changes during walking are dependent upon 338 
the changes in ankle and knee joint angles (Fig. 3 & 4). Although the magnitude of the 339 
between-group differences were relatively small (~2 deg at the ankle and ~4 deg at the 340 
knee), a significantly smaller ankle and knee joint range of motion during walking was 341 
found in the DPN group compared to the controls (Fig. 4). This resulted in significantly 342 
smaller MTC length changes during walking in the diabetes and particularly in the DPN 343 
group compared to controls (Fig. 3; Table 1). The present findings of reduced tendon 344 
elongations are in line with previous work by Cronin et al. (11) showing that the Achilles 345 
tendon length changes during walking are attenuated in long-term diabetic patients, but 346 
without reference to a diabetic peripheral neuropathy group. 347 
During walking the muscle fascicles of the gastrocnemius underwent very little length 348 
change compared to the Achilles tendon and the MTC (Fig. 3) and they could be 349 
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considered as acting near-isometrically. Indeed, near-isometric behaviour of 350 
plantarflexor muscle fascicles has been previously reported in healthy young 351 
populations Fukunaga (18), Lichtwark (25), Ishikawa (23), Roberts (39), which functions 352 
to allow the Achilles tendon to absorb the length changes of the MTC, thereby 353 
facilitating elastic energy storage within the tendon. Although the muscle fascicles were 354 
found to actually shorten very little during the propulsive phase of gait in any group (Fig. 355 
3), the reduced elastic energy contribution from the Achilles during walking in people 356 
with diabetes and particularly in those with DPN indicates that the plantarflexor muscles 357 
would need to contribute a greater proportion of the work, thereby increasing the 358 
metabolic CoW. Although we did not find a greater length change of the gastrocnemius 359 
muscle fascicles for the diabetes groups in the present study, it could be speculated that 360 
the uni-articular soleus muscle undergoes greater shortening in the diabetes groups, 361 
contributing to the higher muscular contribution and increased CoW. Despite the near-362 
isometric behaviour of muscle fascicles during walking, pennation angles underwent 363 
changes in the region of between 22-32 deg, reflecting elongation of the Achilles tendon 364 
and aponeurosis, with smaller pennation angle changes seen in the DPN group (Table 365 
2).     366 
The tendon stiffness data measured during walking in the present study are comparable 367 
with a number of previous in vivo human studies of the Achilles tendon measured using 368 
a dynamometry approach and reporting values ranging between 149 and 207 N/mm 369 
(31, 21, 25, 28). The increased tendon stiffness likely results from increased collagen 370 
cross-linking due to diabetes and DPN (33, 34), but a thicker tendon with a larger cross-371 
sectional area may also play a role if present (21). Also, values for tendon hysteresis 372 
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from the present study measured during walking are comparable to dynamometry-373 
based methods reported previously in the literature for the Achilles tendon in the range 374 
between 5 and 26 % (31, 25, 28, 15, 24). It should be noted, that whilst previous studies 375 
have derived tendon stiffness and hysteresis values from static dynamometry 376 
measurements, the present study is unique in determining these tendon properties 377 
during walking. It should be acknowledged as a limitation, however, that tendon length 378 
changes can result from both tendon loading and also joint rotations. Therefore, 379 
measurements of tendon elongation in the previous and present studies reflect not only 380 
‘true’ elongations resulting from tensile forces, but also elongation due to joint rotations. 381 
Whilst this is more easily ‘corrected’ for with the dynamometry-based approach, the 382 
complexity of the unique approach followed in the present study mean that joint 383 
rotations are more challenging to account for. Nevertheless, the magnitudes of 384 
between-group differences in joint rotations were relatively small and therefore unlikely 385 
to impact on the present findings (Fig. 4; Table 1). 386 
We calculated ankle joint moments using the inverse dynamics technique, which 387 
provides the net joint moment. In calculating the net joint moment, this technique takes 388 
into account agonist and antagonistic moments acting around the joint, but cannot 389 
distinguish differences in for example, the level of antagonist muscle coactivation 390 
between groups. Using this standard approach to calculate Achilles tendon forces, an 391 
assumption is made that that the force generated by all of the plantarflexor muscles acts 392 
through the Achilles tendon. Based on data of muscle physiological cross-sectional area 393 
(17), the soleus and gastrocnemius muscles will contribute 83% of the plantarflexion 394 
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force, but it should be acknowledged that there are other smaller plantarflexor muscles 395 
contributing the remaining 17% of the force that do not act through the Achilles tendon.  396 
The present study has shown reduced Achilles tendon elongation, increased stiffness 397 
and hysteresis during walking in people with diabetes and particularly those with DPN, 398 
compared to controls. The implications of these findings are a reduced storage and 399 
release of elastic energy from the Achilles tendon of diabetes and DPN patients during 400 
walking, presumably requiring a greater contribution to the work from plantarflexor 401 
muscles. The results strongly point towards the reduced energy saving capacity of the 402 
Achilles tendon in diabetes and DPN patients as an important factor contributing to the 403 
increased metabolic CoW in these patients. 404 
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Figure 1. A linear 7.5 MHz probe (A) with 60 mm field of view used for scanning the 585 
gastrocnemius muscle. A custom-built fixation device made of Velcro straps and a 586 
plastic cast moulded to fit the general contour of the calf (B) was used to secure the 587 
probe around the left lower leg, in the mid-sagittal plane of the gastrocnemius muscle 588 
with extra strapping added to further minimise any probe movement (C). 589 
 590 
 591 
Figure 2. Typical sonograph of the GM muscle. The fascicular trajectory between the 592 
two aponeurosis, as well as the pennation angle (α) are highlighted in white. SA, 593 
superficial aponeurosis; MG, gastrocnemius medialis muscle; DA, deep aponeurosis. 594 
 595 
 596 
 597 
 598 
 599 
 600 
 601 
Table 1. Participant characteristics and results from neuropathy assessments. 602 
Variable 
Group 
Ctrl DM DPN 
Age (yr) 55 (7) 57 (8) 61 (7) 
BMI (kg/m2) 26 (4) 28 (4) 29 (5) 
mNDS (Score/10) 1 (1) 2 (1) 7 (2)** 
VPT (Volts) 6.1 (3) 8.2 (4) 27.4 (9)** 
Diabetes duration (years) - 14 (13) 17 (11) 
Type 1 diabetes - 6 4 
Type 2 diabetes - 14 9 
 603 
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Healthy controls (Ctrl, n=23), diabetic patients with no neuropathy (DM, n=20) and 604 
diabetic patients with moderate/severe neuropathy (DPN, n=13). Significant differences 605 
from the Ctrl group are denoted by ** (P<0.01). BMI = body mass index, mNDS = 606 
modified neuropathy disability score, VPT = vibration perception threshold. Values are 607 
means (standard deviations). 608 
 609 
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Table 2. Achilles and plantarflexor muscle-tendon parameters during walking. 610 
 611 
 Ctrl DM DPN 
 Self-selected 1 m/s Self-selected 1 m/s Self-selected 1 m/s 
Walking speed (m/s) 1.43 (0.29) 1.03 (0.17) 1.33 (0.36) 1.04 (0.21) 1.30 (0.34) 0.98 (0.20) 
Stiffness (N/mm) 210 (41) 186 (34) 231 (46)** 194 (39)** 240 (49)** 202 (37)** 
26 
 
Achilles and plantarflexor muscle-tendon parameters during walking for healthy controls (Ctrl; n=23), diabetic 612 
patients with no neuropathy (DM; n=20) and diabetic patients with moderate/severe neuropathy (DPN; n=13). 613 
Values are group means and SD; Significant differences from the Ctrl group are denoted by *(P<0.05) or 614 
**(P<0.01). MTC – muscle-tendon complex; RoM – range of motion. 615 
 616 
Self-selected walking speed 617 
Hysteresis (%) 18 (3) 17 (3) 21 (5)** 19 (4)* 24 (6)** 21 (5)** 
Standing fascicle length (cm) 5.15 (1.5) 5.08 (1.4) 5.19 (1.3) 
Tendon length change (cm) 1.81 (1.0) 1.67 (0.7) 1.66 (0.5)* 1.51 (0.6)* 1.54 (0.8)** 1.47 (0.6)** 
Fascicle length change (cm) 
10-70 % of stance (loading) 
0.58 (0.08) 0.53 (0.19) 0.42 (0.05)** 0.39 (0.06)** 0.38 (0.12)** 0.44 (0.14)** 
Fascicle length change (cm) 
70-100% of stance (unloading) 
0.54 (0.04) 0.50 (0.12) 0.38 (0.04)** 0.33 (0.04)** 0.31 (0.07)** 0.37 (0.11)** 
MTC length change (cm) 
10-70 % of stance (loading) 
1.21 (0.2) 1.11 (0.3) 0.89 (0.3)** 0.81 (0.2)* 0.76 (0.2)** 0.69 (0.1)** 
MTC length change (cm) 
70-100% of stance (unloading) 
1.44 (0.1) 1.20 (0.1) 0.97 (0.1)** 0.84 (0.1)** 0.63 (0.1)** 0.58 (0.1)** 
Tendon length change (cm) 
10-70 % of stance 
1.96 (0.6) 1.71 (0.4) 1.65 (0.3)** 1.26 (0.4)** 1.18 (0.5)** 0.81 (0.4)** 
Tendon length change (cm) 
70-100% of stance 
1.92 (0.4) 1.82 (0.3) 1.63 (0.2)** 1.41 (0.2)** 0.78 (0.3)** 1.15 (0.2)** 
Achilles Tendon forces (N) 2666 (242) 2343 (288) 2609 (167)* 2256 (290)** 2150 (177)** 2288 (241)** 
Ankle RoM (deg) 26.4 (7.9) 25.1 (8.7) 25.3 (7.1)** 24.2 (8.1)** 25.1 (8.6)** 22.3 (9.5)** 
Knee RoM (deg) 69.7 (26.1) 67.8 (24.9) 67.0 (21.5)** 66.0 (21.3)** 64.8 (30.2)** 64.7 (23.5)** 
Pennation angle change (deg) 
10-70% stance (loading) 
26.8 (6.3) 24.9 (3.4) 25.7 (8.9)** 24.7 (5.0)** 25.1 (9.2)* 22.4 (8.0)* 
Pennation angle change (deg) 
70-100% stance (unloading) 
31.9 (9.9) 30.7 (7.2) 29.6 (6.1)** 29.2 (6.9)** 28.8 (8.9)* 22.8 (7.7)** 
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 618 
1.0 m/s 619 
 620 
 621 
Figure 3. Muscle fascicle length, MTC length and tendon length changes, respectively while walking at self-selected speed 622 
and 1.0 m/s. Values are means. Line graphs: Ctrl - solid line (n=23), DM - dotted line (n=20), DPN - dashed line (n=13). 623 
 624 
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Self-selected walking speed 625 
 626 
1.0 m/s 627 
 628 
Figure 4. From left to right: ankle and knee range of motion (RoM) and ankle joint moment (AJM) during stance phase while 629 
walking at self-selected walking speed and 1.0 m/s for healthy controls (Ctrl), diabetic patients with no neuropathy (DM), 630 
and diabetic patients with moderate/severe neuropathy (DPN). Values are means. Line graphs: Ctrl - solid line (n=23), DM - 631 
dotted line (n=20), DPN - dashed line (n=13). 632 
 633 
 634 
 635 
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 636 
Figure 5. Achilles tendon force-elongation curves while walking at self-selected speed 637 
(4a) and at 1 m/s (4b) for healthy controls (Ctrl), diabetic patients with no neuropathy 638 
(DM), and diabetic patients with moderate/severe neuropathy (DPN). Values are 639 
means. Line graphs: Ctrl - solid line (n=23), DM - dotted line (n=20), DPN - dashed line 640 
(n=13). 641 
 642 
 643 
Figure 6. Isometric plantarflexion maximal voluntary contraction (MVC) strength for 644 
healthy controls (Ctrl, n=23), diabetic patients with no neuropathy (DM, n=20) and 645 
diabetic patients with moderate/severe neuropathy (DPN, n=13). Values are means and 646 
SD. Significant differences from the Ctrl group are denoted by ** (P<0.01). 647 
